Tag Archives: business

Hot Investor Mandate: China-Based PE Firm Invests in Various Life Science Sectors, Investing $5-50M from Series A through Pre-IPO in US, Europe, and China

9 Sep

 A China-based private equity firm affiliated with a global investment group has raised multiple funds to date and invests across multiple sectors, including healthcare. The firm is a full-spectrum investor, participating from Series A through pre-IPO and PIPE, and may also consider buyouts and add-on acquisitions for its portfolio. Typical investments range from $5-50M, with the capacity to commit up to $100M per company. While the firm is primarily focused on opportunities in China, it also invests in companies from the US and Europe that present a strong China angle. 

The firm invests opportunistically in the healthcare sector on a case-by-case basis. Areas of interest include biopharma, medical devices and equipment, diagnostics, healthcare IT, and R&D services with significant market potential. The firm is stage-agnostic and will consider products ranging from pre-clinical through market-approved. 

The firm invests in both private and public companies, targeting Chinese businesses as well as US- and Europe-based companies with strategic ties to the China market. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Corporate Venture Fund Seeks in Materials Science and Nutritional Health Companies Across the Globe

9 Sep

A corporate venture capital arm of a global science-based company invests in seed and venture stage companies, generally taking less than 25% ownership. While the firm has previously invested from seed through PIPE, the focus is on companies with products in development or early commercialization. Initial allocations typically range from a few hundred thousand dollars up to $5 million, with additional reserves for follow-on rounds. The firm is targeting approximately 5–10 investments in the next 6–9 months, and over 10 additional investments in the next 2 years. The investment scope is global, with a focus on the U.S., Europe, and Israel.

Within biomedical, the firm seeks materials science companies in orthopedics and soft tissue repair. In addition, the firm actively invests in human nutritional health, with a specific emphasis on personalized nutrition and companies developing nutritional products. This includes start-ups with digital or technology-driven models that enable personalization and precision.

The firm values experienced management teams and typically seeks a board seat, aiming to play an active role in portfolio companies. Strategic alignment with the parent company’s businesses is also an important consideration for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Europe-Based Investment Firm Seeks Therapeutics and Medical Device Companies, Investing Up to €20M Over Company Lifecycle

9 Sep

An institutional alternative investor dedicated to direct investments in the life sciences has offices in Europe. The firm manages total assets under management to over EUR 1 billion. The firm invests EUR 5–20 million per portfolio company and expects to back approximately 20 companies from the current fund. It typically acts as a lead investor, providing equity capital and assuming a 20-40% ownership stake. While the firm primarily targets companies in Europe, around 30% of its portfolio is allocated to global opportunities. 

The firm invests in Therapeutics and Medical Devices. For therapeutics, the focus is on companies with proof of principle demonstrated in late preclinical studies or those in Phase I and beyond. For medical devices, companies must already have some in-human data to be considered. 

The firm seeks active involvement in portfolio management and typically holds board positions. Investment horizons generally range from 2–6 years, with exits often achieved through sales to larger companies positioned to complete commercialization. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Global VC Firm Focuses on Backing Innovations in Therapeutics, Diagnostics, and Digital Health Addressing Aging and Longevity

9 Sep

An investment firm with offices in US, Europe, and Asia typically makes investments from $500K–1.5M, and the firm invests globally. The focus is on innovations aimed at preventing age-associated diseases, extending healthy lifespan, and improving human and animal performance. 
 

Within life sciences, the firm invests primarily in therapeutics and diagnostics, and also considers digital health opportunities. Traditional medical devices are generally out of scope. Areas of interest include gene therapy, telomere attrition, proteostasis, regenerative medicine, personalized diagnostics/biomarkers, preventative therapies, cognitive enhancement, and related fields. The firm is modality-agnostic and stage-opportunistic. 
 

The firm seeks companies with strong, protectable IP with clear ownership, supported by diverse management teams with proven track records, and technologies demonstrating validated proof of concept. Investments undergo a three-step diligence process: initial review, additional review focusing on differentiators such as IP and business model, and final review. The firm is open to leading, co-leading, or co-investing and leverages a strong syndication network of like-minded investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Explore the RESI Boston September 2025 Program Guide 

9 Sep

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022The official program guide for RESI Boston, September 2025 is now available! Redefining Every Stage of Investment (RESI) is designed to connect life science and healthcare innovators with a global network of investors across diverse funding strategies, from Seed through Series B and beyond.

This guide provides a complete overview of what to expect throughout the conference, detailing the content and layout for our in-person event on September 17th. Inside, you’ll find the full agenda, speaker bios, panel descriptions, and essential information to help you navigate your RESI experience. Whether you’re participating in investor meetings, the Innovator’s Pitch Challenge, workshops, or ad hoc networking, this guide is your resource to stay organized and maximize your time at RESI Boston.

Access the full guide here:

Register for RESI Boston

Tags: , , , , , , ,

Genaxis, Silver Sponsor of RESI Boston, Hosts Exclusive Startup Showcase

9 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

LSN is excited to announce Genaxis, a leading South Korea based accelerator and early-stage fund dedicated to deeptech and biotech innovation, as a Silver Sponsor of RESI Boston.

Genaxis is bringing five of Korea’s most innovative biotech and medtech startups to the global stage. These companies will be pitching at RESI Boston on September 17, 2025, where they will showcase breakthrough solutions spanning therapeutics, medical devices, digital health, and enabling technologies.

To provide an additional opportunity for investor engagement, Genaxis will also host an exclusive pre-RESI pitch session the day before the conference. The event will take place on Tuesday, September 16, 2025, 9:00 – 11:00am EST, at CIC Boston (50 Milk St, Boston, MA 02109).

At this session, 5 startups will each deliver a 6-minute pitch followed by a 7-minute Q&A, and active investors and strategic partners are invited to join. Please RSVP below if you are interested in meeting Genaxis and the pitching companies. Brief descriptions are provided below:

RSVP

Bilix, Inc. is a biotechnology company dedicated to developing innovative therapies for intractable diseases in inflammation and cancer, with the mission to improve human health one patient at a time for better and longer lives. Driven by courage and determination, Bilix takes on the challenge of finding cures for conditions long considered incurable. Our goal is to expedite drug development and provide therapeutic answers for patients in urgent need, while upholding a commitment to fairness and accessibility. By delivering cost-effective, equitable treatment solutions, Bilix strives to transform the lives of patients worldwide and bring hope where few options exist.

DeepsonBio is a company specialized in ultrasound devices for treating dementia. By utilizing a non-invasive method, we offer a safe and highly effective treatment for patients with Alzheimer’s dementia and normal pressure hydrocephalus dementia.

Our therapeutic ultrasound device is designed to improve cognitive function in patients with mild cognitive impairment (MCI) and early-stage Alzheimer’s disease, utilizing Multiple Low Intensity Pliant Ultrasound (M-LIPUS) for cerebrofluid stimulation.

Main Business Area:

  • Neurology
  • Neurodegenerative disease
  • Alzheimer’s disease
  • Normal pressure hydrocephalus

EXOSYSTEMS Inc. is a South Korea–based digital health company pioneering AI-driven neuromuscular biomarkers to transform how motor function is assessed, diagnosed, and monitored. Founded in 2017 as a spin-out from ETRI, EXOSYSTEMS develops integrated solutions that combine clinical-grade EMG/IMU sensors with advanced AI analytics to deliver objective, quantitative insights into muscle and motor performance.

Its flagship technologies include the Muscle Function Index (MFI), a digital biomarker platform designed to replace fragmented and subjective in-person motor assessments with standardized, high-resolution measures. These solutions serve both pharmaceutical companies, by providing validated digital endpoints for clinical trials, and hospitals and clinics, by enabling efficient point-of-care diagnostics and patient monitoring.

With $4M secured in VC funding, over $10M in national R&D grants, regulatory recognition from the Korean FDA, and validation studies with Roche Korea, EXOSYSTEMS is positioned to set a new global standard for neuromuscular digital health.

Laon Medi is a digital health company transforming orthodontics with software-driven workflows. Our flagship platform, Laon Ortho, solves the inefficiencies of clear aligner treatment planning, a process that traditionally requires hours of manual work and outsourced lab services. By automating case setup and integrating multimodal data such as CBCT and intraoral scans, Laon Ortho reduces planning time to minutes while allowing clinics to manage cases in-house. This shift improves margins, lowers patient costs, and accelerates adoption of clear aligner therapy. Laon Ortho is commercially deployed in dozens of clinics and labs across Korea, generating post-pilot revenues and validating scalability. The company is now expanding globally with a model that serves clinics, labs, and DSOs, positioning itself as a scalable digital dentistry platform with clear cost advantages and growing international demand.

RadaHaim, founded in 2022, is a biotechnology company pioneering standardized, scalable organoid platforms for drug discovery and toxicology testing. We have developed patient-derived and iPSC-derived liver organoids with consistent size and morphology, enabling reliable disease modeling and drug-induced liver injury (DILI) assays. Our preclinical service platform operates under GLP-inspired workflows, including batch-level QC, reference compound benchmarking, and high-content imaging analytics. By bridging the translational gap between animal studies and clinical outcomes, RadaHaim provides pharmaceutical and biotech partners with more predictive data to accelerate drug development and reduce failures in clinical trials. In addition to CRO services, our long-term goal is to commercialize assay kits that integrate standardized organoids with ready-to-use protocols. Based in Korea and now expanding into the U.S., RadaHaim aims to become a global leader in organoid-based NAMs (New Approach Methodologies) aligned with regulatory acceptance and the future of animal-free testing.

About Genaxis:

Genaxis is a leading accelerator dedicated to supporting deep-tech and biotech startups. We deliver customized acceleration programs, strategic mentoring, and global investor access to help companies grow beyond their local markets. With expertise in investment readiness, cross-border collaboration, and global market entry, Genaxis equips entrepreneurs with the tools and networks they need for sustainable growth. As a Silver Sponsor of RESI Boston 2025, we are committed to connecting innovative startups with global life science investors, fostering collaboration between Korea and the world. Our mission is to empower founders to achieve impactful innovation, create long-term value, and strengthen the global startup ecosystem.

Tags: , , , , , , , ,

Partnering for Growth: DLA Piper on Supporting Life Science Innovation at RESI Boston 

9 Sep

At RESI Boston, global law firm DLA Piper plays a key role in guiding early-stage innovators through the legal and commercial challenges of scaling in the life sciences. In this interview, Lauren Murdza, Co-Chair of Technology & Life Sciences Licensing & Commercial Transactions, shares why DLA Piper chose to sponsor RESI, what the firm looks for in collaborations, and the trends shaping licensing and commercial transactions today.

Lauren Murdza
 CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): What motivated DLA Piper to sponsor RESI Boston, and why do you see value in supporting this conference?

Lauren Murdza (LM): DLA Piper is committed to supporting innovation in the life sciences sector, and RESI Boston offers a unique opportunity to engage directly with early-stage companies and investors. Sponsoring RESI aligns with our mission to be a strategic partner to emerging life science ventures, helping them navigate legal complexities while fostering meaningful connections that drive growth.

CD: From your perspective, what makes RESI a strong platform for connecting with early-stage life science innovators and investors?

LM: RESI creates a unique environment where entrepreneurs, investors, and advisors come together to solve real challenges. For DLA Piper, it’s an opportunity to listen and engage in conversations that matter—how to protect IP, manage data rights, and structure collaborations that attract capital. Those discussions allow us to show how DLA Piper’s integrated approach—combining legal, regulatory, and commercial insight—helps companies accelerate their next milestone.

CD: Can you share what types of companies, technologies, or partners DLA Piper is most interested in engaging with during RESI?

LM: We’re particularly interested in companies developing novel therapeutics, diagnostics, digital health platforms, and medical devices. Our team seeks to engage with founders and executives who are navigating the transition from concept to commercialization and who value strategic legal guidance in areas such as licensing, IP protection, and regulatory compliance.

CD: How does your team at DLA Piper support life science and healthcare companies as they move from early-stage development to commercialization?

LM: DLA Piper supports clients across the full lifecycle of a company—from corporate formation and IP strategy to licensing, financing, and M&A. We help clients identify the core aspects of their technology, assess patentability, and streamline initial filings to create contingent assets that support fundraising. What sets DLA Piper apart is our ability to deliver this seamlessly across jurisdictions, giving clients the confidence that their legal strategy scales with their business.

CD: Are there particular trends or challenges in licensing and commercial transactions that you think entrepreneurs at RESI should be especially mindful of?

LM: We’re seeing three big themes. First, clarity on data and AI rights is critical—investors want to know who owns what and how data can be used, especially across borders. Second, deal structures are evolving, with more options-to-license, milestone-based terms, and royalty monetization to help bridge funding gaps. Finally, regulatory and supply chain issues—from FDA expectations to manufacturing scale-up—are showing up earlier in negotiations. At DLA Piper, we help clients anticipate these challenges so they don’t slow down growth.

CD: What does DLA Piper hope to accomplish through its participation at RESI Boston this year?

LM: We aim to deepen our engagement with the life sciences community, share actionable insights through workshops and panels, and identify promising companies that could benefit from our legal and strategic expertise. RESI Boston is a chance to listen, learn, and contribute to the ecosystem that’s shaping the future of healthcare innovation.

CD: Looking ahead, what excites you most about the current life science innovation landscape, and how does DLA Piper plan to play a role in advancing it?

LM: We’re excited by the convergence of AI, data science, and biotechnology, which is accelerating discovery and personalization in medicine. DLA Piper plans to continue supporting innovators by offering forward-thinking legal solutions and fostering connections that help companies bring transformative technologies to the market.

Tags: , , , , , , , , , , , , , , ,

← Older Entries
Newer Entries →